Immunogenicity and safety of Pandemic H1N1 2009 Influenza vaccine for HIV-1 patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F12%3A%230000136" target="_blank" >RIV/00064211:_____/12:#0000136 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.4149/av_2012_04_349" target="_blank" >http://dx.doi.org/10.4149/av_2012_04_349</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Immunogenicity and safety of Pandemic H1N1 2009 Influenza vaccine for HIV-1 patients

Popis výsledku v původním jazyce

The advent of the 2009 H1N1 pandemic influenza has raised concerns about the immunogenicity and safety of vaccines against the new virus, especially in immunocompromised individuals. In our study we evaluated the immunogenicity and safety of pandemic influenza vaccine in 34 HIV-1 infected patients. Antibody production was tested by hemagglutinin inhibition assay according to the World Health Organization methodology. No serious adverse event was observed among the vaccinees, only nine individuals (26.5%) reported moderate pain at the application site lasting maximally two days. The protection rate after vaccination of HIV-1 infected individuals with a single dose of studied pandemic H1N1 influenza vaccine, albeit low if compared with normal population,met the criteria set by European Committee for Medicinal Products for minimal immunogenicity.

Název v anglickém jazyce

Immunogenicity and safety of Pandemic H1N1 2009 Influenza vaccine for HIV-1 patients

Popis výsledku anglicky

The advent of the 2009 H1N1 pandemic influenza has raised concerns about the immunogenicity and safety of vaccines against the new virus, especially in immunocompromised individuals. In our study we evaluated the immunogenicity and safety of pandemic influenza vaccine in 34 HIV-1 infected patients. Antibody production was tested by hemagglutinin inhibition assay according to the World Health Organization methodology. No serious adverse event was observed among the vaccinees, only nine individuals (26.5%) reported moderate pain at the application site lasting maximally two days. The protection rate after vaccination of HIV-1 infected individuals with a single dose of studied pandemic H1N1 influenza vaccine, albeit low if compared with normal population,met the criteria set by European Committee for Medicinal Products for minimal immunogenicity.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta virologica

ISSN

1336-2305

e-ISSN

—

Svazek periodika

56

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

3

Strana od-do

349-351

Kód UT WoS článku

000313403400011

EID výsledku v databázi Scopus

—